Media exposure by GlobalData

Media exposure by GlobalData

Lumosa partners with Camargo for LT1001

Lumosa Therapeutics Partners with Camargo Pharmaceutical Services in the Development of Naldebain(R) in the US

USFDA approved the phase 1 trial for LT3001

Lumosa Therapeutics Co., Ltd., (TPEx: 6535, hereinafter 'Lumosa') is pleased to announce that its lead drug candidate for acute ischemic stroke, LT3001, has received approval from the US FDA to begin Phase I clinical trials. The first clinical trial is a double-blinded dose escalating study in healthy volunteers and expected to be completed in the first half of 2018.

Lumosa's LT1001 approved by Taiwan FDA

Lumosa Therapeutics Co., Ltd. (Lumosa, 6535.TWO) announced the approval of LT1001, a long-acting analgesic injection (product name: Naldebain®) by Taiwan Food and Drug Administration (TFDA) today (March 6, 2017).  Naldebain®, soon to be launched in Taiwan, is 100% "made in Taiwan"; from concept through product development, clinical trials, and dossier compilation. 

Lumosa scientist spoke at 2017 International Stroke Conference

Lumosa Therapeutics Co., Ltd. (Lumosa, 6535.TWO) announced the preclinical study results of its drug candidate for the treatment of acute ischemic stroke at the International Stroke Conference 2017 (ISC).

Naldebain® draws attention at Taiwan Society of Colon and Rectal Surgeions

Dr. Chien-Yuh Yeh was invited to report the phase 3 trial results of Naldebain® (dinalbuphine sebacate) I.M. Injection (also called LT1001) at the Annual Meeting of Taiwanese Society of Colon and Rectal Surgeons held in Kaohsiung, Taiwan on December 10, 2016.  The Society celebrated its 30th anniversary since inception.  Speaker Dr. Yeh is a practicing surgeon at Chang Gung Memorial Hospital and one of the lead investigators of this phase 3 trial. The title of his presentation was “A Phase III Trial of a Novel Long Acting Painkiller,” which highlighted the unique safety and long-lasting efficacy profile of the product.